HONG KONG – In one of the first issues since Mainland China regulator lifted a ban on initial public offerings (IPOs), Zhejiang Wolwo Bio-Pharmaceutical Co. (SZ: 300357) plans to offer as many as 30 million shares for as much as ¥20.05 (US$3.30) per share.